TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Rigel Pharmaceuticals, Inc. Long Term Shareholder Investigation

  • If you are a current long term investor in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) securities, including those who purchased RIGL shares in 2008 or earlier and continue to hold those shares, you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

December 18, 2012 (Update) -- On Dec. 13, 2012, before the market opened, Rigel Pharmaceuticals, Inc. announced the results of a a treatment for rheumatoid arthritis that it is partnering with AstraZeneca PLC. Rigel Pharmaceuticals, Inc. said that while the study had two primary objectives and the treatment failed to meet one of two main goals. Rigel faces a pending lawsuit on behalf...



You must register (for free) or login to view the entire investigation.

Click here to Sign In or Register (for a free account)

@screen width:
@theme:
@breakpoints:
@layout: